The effect of Oleoylethanolamide supplementation on oxidative stress parameters in multiple sclerosis patients

The requested reference [b1f7a6e4f230db1e02e5fd1353224ca66c367e1d] no longer exists in our database. It has been replaced by the current reference: [114569aa129338f3fb4267b373f44cac317a0414]

Authors
Category Primary study
Registry of TrialsIranian Registry of Clinical Trials
Year 2021
INTERVENTION: Intervention 1: Intervention group: Take two oleoyl ethanamide supplements (250 mg) daily orally for six weeks. Supplements are provided by Karen Company. Intervention 2: Control group: Take two placebo capsules daily (capsule that is not oleoyl ethanlamide but patients have not been told about it) for 6 weeks. CONDITION: Multiple sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: Catalase enzyme activity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer. Cholesterol. Timepoint: Before and after the intervention. Method of measurement: Laboratory. Interleukin 17. Timepoint: Before and after the intervention. Method of measurement: ELISA. PLT. Timepoint: Before and after the intervention. Method of measurement: Laboratory. Protein oxidation. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer. Red blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory. TG. Timepoint: Before and after the intervention. Method of measurement: Laboratory. TNF‐a. Timepoint: Before and after the intervention. Method of measurement: ELISA. Total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer. UREA. Timepoint: Before and after the intervention. Method of measurement: Labratory. White blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory. INCLUSION CRITERIA: MS type of relapsing_remitting MS patients are treating with beta interferon Willingness to cooperate Patients with an age range of 20 to 40 years
Epistemonikos ID: fbfab406d2f5a5b246b5aa68922df65f96888d75
First added on: Mar 31, 2022